After 15 further drugs were announced as being opened up to price negotiation by the US Centers for Medicare & Medicaid Services, the response from the Association for Accessible Medicines to the US Department of Health and Human Services was clear and unambiguous: the Inflation Reduction Act’s price negotiation scheme doesn’t work.
AAM Hits Out At ‘Flawed’ Medicare Price Negotiation List
Responding to the announcement by the US Centers for Medicare & Medicaid Services of the 15 additional drugs that will soon be subject to price negotiation – including Ozempic, Rybelsus and Wegovy – the Association for Accessible Medicines has called out the “short-sighted government price setting scheme” for undermining generic and biosimilar competition.
More from Drug Pricing
• By
After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.
• By
In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.
More from Generics Bulletin
• By
Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
Trihexyphenidyl tablets in two different strengths led a raft of UK generic price rises in March, according to the latest figures from WaveData.